|
|
|
|
|
|
|
|
|
sponsored by
|
|
|
|
Katalyze raises $10.5M as five of the top twenty global pharma companies run its agents in production
|
| Deviation and OOS investigations stall because the answers sit fragmented across Veeva, SAP, historians, and paper. Built with more than a hundred tenured scientists from companies including Sanofi, Pfizer, and Lilly, Katalyze grounds its agents in an Operational Data Layer, so every answer traces to a source, and deploys into existing GxP systems with no change to architecture. Customer teams have cut deviation investigations by 50%, lifted throughput 25%, and helped deliver more than 10 million doses to patients. |
|
|
|
|
|
|
|
|
|
|
|
When you're the world's largest pharma company by market cap, it comes with its share of perks. Eli Lilly has put the pedal to the metal by accounting for nearly 25% of the industry's biotech acquisitions in the first half of the year. And Lilly isn't limiting itself to certain therapeutic areas: Chief dealmaker Jacob Van Naarden told Kyle LaHucik that it's able to "go shopping in aisles of the supermarket that are a little less populated." Read Kyle's piece here. |
|
|
|
Alex Hoffman |
Copy Chief and News Editor, Endpoints News
|
|
|
|
|
|
|
by Kyle LaHucik
|
Riding on its trillion-dollar heftand successes in treating obesity, Eli Lilly has now become a force in one area where it hasn’t historically been... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus news on Alchemab, Scipher and Forte. 💉 Ipsen’s Dysport aces Phase 3 migraine trials: The biotech’s injectable neurotoxin metthe primary endpoint of reducing... | |
|
|
|
|
|
|
|
|
by Elizabeth Cairns
|
AstraZeneca’s shares dropped in early trading Thursday after a heart disease treatment it is developing with Ionis Pharmaceuticals surprisingly failed in a late-stage trial. The... | |
|
|
|
|
|
|
by Ayisha Sharma
|
After two high-profile trial failures over the past year, GSK is breaking off a deal that features $700 million upfrontthat it signed with Alector... | |
|
|
|
|
|
|
|
|
by Nicole DeFeudis
|
Prime Medicine is headed for the clinic after winning a dispute with Beam Therapeutics, another gene editing biotech with roots in the same lab. Arbitrators... | |
|
|
|
